ANTH Shariah Compliance
Screening Methodology: AAOIFI
LOCKED
Anthera Pharmaceuticals Inc. Stock Analysis ANTH
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life-threatening diseases. The company is headquartered in Hayward, California and currently employs 21 full-time employees. The company went IPO on 2010-03-02. The firm has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.
Read More ANTH Chart
Anthera Pharmaceuticals Inc vs S&P 500 Comparative Returns
Analysis of ANTH stock performance compared to the broader market (S&P 500) across multiple timeframes.
YTD Performance
- Anthera Pharmac... (ANT...) 9900%
- S&P 500 5.05%
Anthera Pharmac... Outperformed S&P 500 by 9894.95%
1Y Performance
- Anthera Pharmac... (ANT...) 9900%
- S&P 500 13.06%
Anthera Pharmac... Outperformed S&P 500 by 9886.94%
3Y Performance
- Anthera Pharmac... (ANT...) 9900%
- S&P 500 62.03%
Anthera Pharmac... Outperformed S&P 500 by 9837.97%
5Y Performance
- Anthera Pharmac... (ANT...) -99.64%
- S&P 500 99.19%
Anthera Pharmac... Underperformed S&P 500 by 198.83%
FAQ's
Halal stocks refer to shares of companies that comply with Islamic finance principles, meaning they do not engage in businesses related to alcohol, gambling, pork, or interest-based financial services.